Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer

Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer

Any type of Cancer

Unknown

2

Start Date 01/01/2007

Age of Trial (yrs) 17.3

Palliative

KIT/PDGFRA inhibitor

Block KIT

GIST not specified. GIST patient enrollment unknown.

GCO 06-0906

Pfizer Mt. Sinai School of Medicine

See site contact info below

Oral

Johnny Kao called and wanted to make us aware of this trial. It will accept GIST patients although none have enrolled. Last verified 3/30/2009.

"Radiation therapy is an effective modality of treating cancer. Until recently, radiation for metastases was used only to relieve symptoms resulting from local tumor growth. Technological advances, including stereotactic radiotherapy, allow for radiation to be more precisely delivered to the tumor while sparing nearby normal organs. Stereotactic radiotherapy can completely eradicate local tumors with minimal side effects. Stereotactic radiotherapy has never been combined with drug therapy. Sutent is a new F.D.A. approved cancer therapy that targets tumor blood vessels. It is effective against two types of cancer that rarely respond to chemotherapy (GI stromal tumors and kidney cancer). We propose combining biologically targeted drug therapy with physically targeted stereotactic radiotherapy. Our goal is to determine if this is a safe regimen and the best method of combining these treatments."

"Ultimately, our goal is to cure some patients with previously incurable metastatic cancer with this combination."